TP53 and cancer: The compound also promotes p53-dependent apoptosis in isogenic cancer cell lines with either wild-type or null p53.591 Compound 1, a dual USP7 and USP47 inhibitor with moderate potency, elevates p53 protein levels and triggers apoptosis in cancer cells.